SynthesisEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology2015
Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies.
Synthesis in European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 4 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Suicidal risk in patients with aggression in schizophrenia: a systematic review.Frontiers in psychiatry · 2025Pooled it
- What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review.Paediatric drugs · 2023Pooled it
- Poor Insight in Schizophrenia Patients in China: a Meta-Analysis of Observational Studies.The Psychiatric quarterly · 2020Pooled it
- Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review.Journal of clinical psychopharmacology · 2016Pooled it
- Clinical insight among persons with schizophrenia spectrum disorders treated with amisulpride, aripiprazole or olanzapine: a semi-randomised trial.BMC psychiatry · 2023Trial
- Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study.Psychiatry and clinical neurosciences · 2022Trial
- Adherence to antipsychotic medication among homeless adults in Vancouver, Canada: a 15-year retrospective cohort study.Social psychiatry and psychiatric epidemiology · 2016Trial
- Clinical insight in schizophrenia: Time-specific associations with symptoms, cognition and antipsychotic mechanisms.Schizophrenia research. Cognition · 2027Article
- Poor insight and self-disorders in schizophrenia: an empirical study.European archives of psychiatry and clinical neuroscience · 2026Article
- Clinical and cognitive insight in schizophrenia and their relationship with neurocognition and metacognition: a narrative review.Frontiers in psychiatry · 2026Review
- Review
- The Psychosocial Impact of Insight Paradox and Internalized Stigma in Chronic Psychotic Disorders.Behavioral sciences (Basel, Switzerland) · 2025Article
- Impaired insight in schizophrenia is associated with higher frontoparietal cerebral blood flow: an arterial spin labeling study.Schizophrenia (Heidelberg, Germany) · 2025Article
- Effect of self-stigma on personal recovery: sex differences in people with psychotic spectrum disorders.Frontiers in global women's health · 2025Article
- Medication non-adherence in re-admitted patients at a psychiatry hospital: A qualitative study.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2025Article
- Global Assessment of Medication Adherence: Correlational Analyses of a Brief Tool for Evaluating Medication Adherence in Patients with Severe Mental Disorders.Psychiatry and clinical psychopharmacology · 2024Article
- Failure to treat: an American policy perspective.CNS spectrums · 2024Review
- Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis Recurrence.Schizophrenia bulletin · 2024Article
- Predictors of medication adherence in a large 1-year prospective cohort of individuals with schizophrenia: insights from the multicentric FACE-SZ dataset.Translational psychiatry · 2023Article
- Cortical thinning in relation to impaired insight into illness in patients with treatment resistant schizophrenia.Schizophrenia (Heidelberg, Germany) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 4 countries.
Funding
Abstract
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) obtained a sample of 1493 chronic schizophrenia patients. The European First Episode Schizophrenia Trial (EUFEST) studied a sample of 498 patients. We have combined these two samples to study the predictors and correlates of adherence to treatment. Here we report on adherence to pharmacological treatment at the six and twelve month assessments of these trials with a combined subsample of 1154 schizophrenia patients. Individual patients׳ data were used for analyses. We used logistic regression to examine the effects of substance use, akathisia, parkinsonism, dyskinesia, hostility, and insight on pharmacological adherence. The results showed that reduced adherence to pharmacological treatment was associated with substance use (p=0.0003), higher levels of hostility (p=0.0002), and impaired insight (p<0.0001). Furthermore, poor adherence to study medication was associated with earlier discontinuation in the combined data. The clinical implications of the results point to the importance of routine assessments and interventions to address patients׳ insight and comorbid substance use and the establishment of therapeutic alliance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.